Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes-Reference-Cited by-同舟云学术

Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Published:2024-04 Issue:4 Volume:88 Page:106130
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Hayward Gail^ORCID,Yu Ly-Mee^ORCID,Little Paul,Gbinigie Oghenekome^ORCID,Shanyinde Milensu^ORCID,Harris Victoria,Dorward Jienchi^ORCID,Saville Benjamin R.,Berry Nicholas^ORCID,Evans Philip H.,Thomas Nicholas P.B.,Patel Mahendra G.,Richards Duncan,Hecke Oliver V.,Detry Michelle A.,Saunders Christina,Fitzgerald Mark,Robinson Jared^ORCID,Latimer-Bell Charlotte,Allen Julie,Ogburn Emma^ORCID,Grabey Jenna^ORCID,de Lusignan Simon,Hobbs FD Richard,Butler Christopher C.

Funder

NIHR

Publisher

Elsevier BV

Reference41 articles.

1. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro;Caly;Antivir Res,2020

2. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice;Zhang;Inflamm Res,2008

3. Nonspecific membrane bilayer perturbations by ivermectin underlie SARS-CoV-2 in vitro activity;Eastman;bioRxiv,2023

4. Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with in-vitro effective drug ivermectin;Sen Gupta;J Biomol Struct Dyn,2022

5. Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results;Izcovich;J Clin Epidemiol,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes;Journal of Infection;2024-10

2. Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial;The Lancet Infectious Diseases;2024-09

3. Ivermectin-induced toxicity in HepG2 cells and the protective effect of tetrahydrocurcumin and vitamin C;Drug and Chemical Toxicology;2024-08-19

4. Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity;Heliyon;2024-08

5. Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses;Viruses;2024-04-22